Next 10 |
home / stock / gcvrz / gcvrz news
2024-07-08 12:30:52 ET Summary Eli Lilly and Company is set to acquire Morphic Holding for $3.2bn. Morphic is focused on autoimmune disease drugs. Morphic's MORF-057 has a similar MoA to Takeda's ~$5bn per annum selling drug entyvio, but it is orally available, unlike the injectab...
2024-07-03 06:52:20 ET More on Sanofi, Regeneron, etc. Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (...
2024-06-11 07:49:42 ET More on Sanofi, Regeneron, etc. Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript) Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) ...
2024-06-11 07:23:55 ET More on GSK GSK plc: Long-Term Cash Cow GSK Breathes New Life Into Asthma Treatment With Depemokimab GSK plc (GSK) Q1 2024 Earnings Call Transcript GSK, SpringWorks end collaboration agreement GSK wins FDA nod to expand label fo...
2024-06-07 14:42:51 ET Summary Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42...
2024-06-06 08:04:56 ET More on Sanofi, Novavax, etc. Novavax: Sanofi Partnership Revitalizes My Magnum Opus Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript Novavax Ditches 'Going Concern,' Embraces Sanofi Safety Net (Rating Upgrade) Bird flu death in Me...
2024-05-31 06:49:06 ET More on Sanofi, Regeneron, etc. Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Regeneron Pharmaceuticals, Inc. (REGN) Q1...
2024-05-30 13:46:56 ET More on CureVac, GSK, etc. GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT ...
2024-05-30 07:04:27 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Moderna down ~9%, likely ending 10-sessio...
2024-05-22 15:38:02 ET More on Bristol-Myers, Sanofi, etc. Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript) Brist...
News, Short Squeeze, Breakout and More Instantly...
Sanofi Contingent Value Right (Expiring 12/31/2020) Company Name:
GCVRZ Stock Symbol:
NASDAQ Market:
Sanofi Contingent Value Right (Expiring 12/31/2020) Website:
* The British Pharmacological Society awards Cablivi® (caplacizumab), the first new treatment in 30 years for acquired Thrombotic Thrombocytopenic Purpura (aTTP), Drug Discovery of the Year 2020 * TTP is a rare blood clotting disorder with 330 people known to be affected i...